BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 17654055)

  • 1. Prophylactic platelet transfusion in children with thrombocytopenic disorders: a retrospective review.
    Ferrara M; Capozzi L; Coppola A; Save G; Coppola L
    Hematology; 2007 Aug; 12(4):297-9. PubMed ID: 17654055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombocytopenia in the neonate.
    Roberts I; Stanworth S; Murray NA
    Blood Rev; 2008 Jul; 22(4):173-86. PubMed ID: 18433954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haematological causes of thrombocytopenia in children at Aga Khan University Hospital, Karachi.
    Jawaid A
    J Pak Med Assoc; 2015 Apr; 65(4):347-59. PubMed ID: 25976563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An audit of platelet transfusion within the Wellington Cancer Centre.
    Buhrkuhl DC; Karlsson MK; Carter JM
    Intern Med J; 2012 Jan; 42(1):65-70. PubMed ID: 21040321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal blood loss: A quantitative method of evaluating hemostasis in patients with thrombocytopenia.
    Slichter SJ; Gernsheimer T; LeBlanc R; Townsend-McCall D; Jones MK; Cuaron L; Bolgiano D
    Transfusion; 2021 Feb; 61(2):393-403. PubMed ID: 33166412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura.
    Duffy SM; Coyle TE
    J Clin Apher; 2013 Oct; 28(5):356-8. PubMed ID: 23720092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
    Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT; Winton EF; Khoury HJ
    Cancer; 2013 Nov; 119(21):3784-7. PubMed ID: 23921838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children.
    Glanz J; France E; Xu S; Hayes T; Hambidge S
    Pediatrics; 2008 Mar; 121(3):e506-12. PubMed ID: 18310170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding manifestations in severely thrombocytopenic children with immune thrombocytopenic purpura.
    Chandra J; Ravi R; Singh V; Narayan S; Sharma S; Dutta AK
    Hematology; 2006 Apr; 11(2):131-3. PubMed ID: 16753855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses.
    Arnold DM; Crowther MA; Cook RJ; Sigouin C; Heddle NM; Molnar L; Cook DJ
    Transfusion; 2006 Aug; 46(8):1286-91. PubMed ID: 16934061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia.
    Vinholt PJ; Alnor A; Nybo M; Hvas AM
    Platelets; 2016 Sep; 27(6):547-54. PubMed ID: 27025360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions to reduce platelet prophylactic transfusions in patients with hypoproliferative thrombocytopenia: providing patients with the full benefit.
    Vamvakas EC; Hitzler WE
    Clin Lab; 2013; 59(5-6):459-64. PubMed ID: 23865342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triggers for prophylactic use of platelet transfusions and optimal platelet dosing in thrombocytopenic dogs and cats.
    Abrams-Ogg AC
    Vet Clin North Am Small Anim Pract; 2003 Nov; 33(6):1401-18. PubMed ID: 14664205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet transfusion goals in oncology patients.
    Fasano RM; Josephson CD
    Hematology Am Soc Hematol Educ Program; 2015; 2015():462-70. PubMed ID: 26637759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome.
    Lum LG; Tubergen DG; Corash L; Blaese RM
    N Engl J Med; 1980 Apr; 302(16):892-6. PubMed ID: 6767187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired Thrombotic Thrombocytopenic Purpura in a 5-Year-old Child With Wiskott-Aldrich Syndrome.
    Özdemir Ö; Orhan MF; Büyükavcı M; Görükmez O
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e434-e437. PubMed ID: 33769392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization.
    Savani BN; Dunbar CE; Rick ME
    Am J Hematol; 2006 Mar; 81(3):218-9. PubMed ID: 16493611
    [No Abstract]   [Full Text] [Related]  

  • 19. Determination of bleeding risk in thrombocytopenic patients with platelet transfusion therapy.
    Kretschmer V; Huss B; Weber S; Bewarder S; Schulzki T; Köppler H; Heimanns J
    Beitr Infusionsther Transfusionsmed; 1994; 32():434-6. PubMed ID: 9422122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
    Navarro JT; Hernández JA; Ribera JM; Sancho JM; Oriol A; Pujol M; Millá F; Feliu E
    Haematologica; 1998 Nov; 83(11):998-1000. PubMed ID: 9864920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.